Australia markets open in 9 minutes

BridgeBio Pharma, Inc. (BBIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
25.62+0.15 (+0.59%)
At close: 04:00PM EDT
25.74 +0.12 (+0.47%)
After hours: 06:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.77B
Enterprise value 6.07B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)445.69
Price/book (mrq)N/A
Enterprise value/revenue 652.60
Enterprise value/EBITDA -10.74

Trading information

Stock price history

Beta (5Y monthly) 1.03
52-week change 382.45%
S&P500 52-week change 324.19%
52-week high 344.32
52-week low 312.75
50-day moving average 329.31
200-day moving average 330.87

Share statistics

Avg vol (3-month) 31.7M
Avg vol (10-day) 31.59M
Shares outstanding 5187.13M
Implied shares outstanding 6184.45M
Float 8113.92M
% held by insiders 15.27%
% held by institutions 190.51%
Shares short (15 Apr 2024) 415.07M
Short ratio (15 Apr 2024) 49.67
Short % of float (15 Apr 2024) 412.87%
Short % of shares outstanding (15 Apr 2024) 48.17%
Shares short (prior month 15 Mar 2024) 413.41M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-10,123.90%

Management effectiveness

Return on assets (ttm)-64.07%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)9.3M
Revenue per share (ttm)0.06
Quarterly revenue growth (yoy)-6.70%
Gross profit (ttm)N/A
EBITDA -592.95M
Net income avi to common (ttm)-643.2M
Diluted EPS (ttm)-3.95
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)434.88M
Total cash per share (mrq)2.47
Total debt (mrq)1.74B
Total debt/equity (mrq)N/A
Current ratio (mrq)3.32
Book value per share (mrq)-7.74

Cash flow statement

Operating cash flow (ttm)-527.72M
Levered free cash flow (ttm)-249.07M